SERPINE1, serpin family E member 1, 5054

N. diseases: 770; N. variants: 23
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 AlteredExpression disease BEFREE It was found that PAI1 expression was significantly higher in HCC than in adjacent liver tissues. 31640087 2020
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 Biomarker disease BEFREE We documented higher serum PAI-1 in HCV-induced HCC than viral infection-free controls, but interestingly, lower than HCV-induced liver cirrhosis patients.This was not genotype related. 27459171 2016
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 Biomarker disease BEFREE HIF-2alpha-dependent PAI-1 induction contributes to angiogenesis in hepatocellular carcinoma. 25489981 2015
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 AlteredExpression disease BEFREE CASE suppresses DEN-induced hepatocarcinogenesis by inhibiting fibrosis and PAI-1 mRNA transcription, suggesting its potential clinical application in preventing and treating human HCC. 24247078 2014
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 Biomarker disease BEFREE Elevated levels of plasminogen activator inhibitor-1 (SERPINE1/PAI-1) have been reported in patients with hepatocellular carcinoma (HCC) associated with viral infection. 22798504 2012
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 AlteredExpression disease BEFREE Furthermore, both rosiglitazone and pioglitazone significantly induced, whereas bezafibrate did not affect PAI-1 mRNA expression in the human liver carcinoma cell line HepG2. 21757225 2011
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 GeneticVariation disease BEFREE The results suggest that PAI-1 genotypes could be an important factor contributing to increased susceptibility and pathological development of HCC in Taiwanese population. 20706793 2010
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 AlteredExpression disease BEFREE Protein expression in hepatoma HepG2 cells stimulated by TGF-beta(1) was analyzed by western blotting and plasminogen activator inhibitor type 1 (PAI-1) transcriptional activity in HepG2 cells was evaluated. 19793165 2010
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 AlteredExpression disease BEFREE Here, we examined whether adenoviral-mediated expression of a constitutively active form of FoxO1 (Ad-CA-FoxO1) inhibited insulin-stimulated PAI-1 expression in human HepG2 hepatocellular liver carcinoma cells and mouse AML12 hepatocytes. 19563779 2009
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 AlteredExpression disease BEFREE The aim of our study was to improve the detection of hepatocellular carcinoma (HCC) by measuring alfa-fetoprotein (AFP) in addition to other molecular markers by estimating the plasma levels of human catalytic fraction of reverse telomerase (hTERT) DNA, plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (t-PA) in 75 patients with liver desease. 18383849 2008
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 AlteredExpression disease BEFREE Cotransfection of human or rat PAI-1 promoter luciferase constructs with expression vectors for wild-type USF-2 or USF-2 mutants in human HepG2 and rat H4IIE cells as well as in primary rat hepatocytes revealed that the effects of USF on PAI-1 expression depend on the cell type rather than the promoter context and that the USF-specific region domain of USF accounts for the observed cell type-specific effects. 16330554 2006
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 Biomarker disease LHGDN In conclusion, distortion of autocrine TGF-beta signals in human HCC accelerates their malignant potential by enhancing cell growth as well as PAI-1 and VEGF production. 12700666 2003
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 Biomarker disease BEFREE In conclusion, distortion of autocrine TGF-beta signals in human HCC accelerates their malignant potential by enhancing cell growth as well as PAI-1 and VEGF production. 12700666 2003
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 Biomarker disease BEFREE Adhesion molecules (E-cadherin, catenins, serum intercellular adhesion molecule-1, CD44 variants), proteinases involved in the degradation of extracellular matrix (MMP-2, MMP-9, uPA, uPAR, PAI), as well as other molecules have been regarded as biomarkers for the malignant phenotype of HCC, and are related to prognosis and therapeutic outcomes. 12046056 2002
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 AlteredExpression disease BEFREE The transcriptional induction of plasminogen activator inhibitor-1 and p21(WAF1/CIP1) by TGF-beta were detected in all HCC cell lines, implying that the molecular integrity of the TGF-beta receptors might be intact. 11906173 2002
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 Biomarker disease BEFREE To assess the role of PAI-1 in invasion and proliferation of hepatocellular carcinoma (HCC) cells, HLE cells were transfected with a vector capable of expressing an antisense PAI-1 transcript. 10470287 1999
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 Biomarker disease BEFREE We have analyzed the regulation of PAI-1 mRNA accumulation by interleukin (IL)-1, IL-6, and dexamethasone, known mediators of the acute phase response, in HepG2 cells, a highly differentiated human hepatoma cell line that produces a broad spectrum of acute phase proteins including PAI-1. 8034668 1994
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 Biomarker disease BEFREE Thus, these data clearly show that LRP is the major cell-surface receptor responsible for t-PA.PAI-1 complex binding and endocytosis on human hepatoma HepG2 cells and extend the multifunctional nature of LRP as an endocytosis receptor for several structurally and functionally distinct ligands. 8389767 1993
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 Biomarker disease BEFREE The hepatoma cell line Hep G2 has been shown to synthesize PAI-1 in response to insulin. 8387542 1993
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 AlteredExpression disease BEFREE In the current work we have analyzed the regulation of vitronectin by transforming growth factor-beta 1 (TGF beta 1) in this hepatoma cell line by Northern hybridization, polypeptide and immunoprecipitation analyses and compared the response to another TGF beta-regulated gene, plasminogen activator inhibitor (PAI-1). 1712727 1991